TRADERPUNKAI-generated research. Not investment advice.TraderPunk is operated by Clickable Company Limited.
PerformanceTermsPrivacyDisclaimerSupport© 2026
Skip to content
TRADERPUNK
StocksPerformancePricingSample report
NYSE · Health Care · Drug Manufacturers - General

JNJ

Johnson & Johnson

Makes prescription drugs and medical devices, having spun off its consumer health brands into a separate company.

$260.35-0.66%
Close · 2026-08-14
Current callSubscribers2026-08-14
$180$200$220$240$260
NovFebMayAug
Market context
$168.51
$274.9052-week range, last close at 86% of the range
1W
+0.43%
1M
+5.40%
3M
+15.50%
6M
+8.13%
YTD
+27.20%
1Y
+52.73%
Avg vol 20d
7.2M
RVOL
0.54
HOLD band
Fundamentalsas of 2026-08-14
Mkt cap
$627.42B
P/E
30.2
Fwd P/E
21.2
EPS
$8.62
Div yield
2.06%
Beta
0.23
Employees
138.2K
Next earnings
2026-10-13
Rating & verdict historyoldest → newest
  1. ✓

100.0% correct+0.99% avg moveBUY 0/0 · HOLD 1/1 · SELL 0/0

DateCallOutcomeReturnTakeaway
2026-08-14Subscribers——Subscribe to read
2026-08-13Subscribers——Subscribe to read
2026-08-12Subscribers——Subscribe to read
2026-08-11Subscribers——Subscribe to read
2026-08-10Subscribers
±1.28%
—
—
Subscribe to read
2026-08-07HOLD✓+0.99%Maintain JNJ as a HOLD with a 12-18 month horizon, as the structural bull case is substantially priced in after the 60% rally and the technical setup shows unambiguous momentum deterioration (MACD bearish cross, RSI cooling, ATR +40%). Entry is disciplined: 2-3% add on 50 SMA retest at $247.73 with RSI > 45, scaling to 5% on 200 SMA test at $226.49 with MACD confirmation, with a stop below $245 invalidating the constructive setup and fair value near $270.